Sanket Koul

Experts say OAds, insulin to dominate anti-diabetes market, with semaglutide patent loss leading to possible price erosion, value moderation

The patent in question is due to lapse in March next year. The court is scheduled to take up Natco's challenge for further hearing in February

10-15% EWS/LIG reservation in all housing projects proposed, along with tax exemption for developer profits on affordable housing

With India importing about 70 per cent of its medical devices, the Department of Pharmaceuticals has invited proposals under two sub-schemes to reduce import dependence and support clinical studies

The Union Health Ministry has prohibited manufacture and sale of oral nimesulide formulations above 100 mg for human use, citing liver toxicity risks and acting on ICMR and DTAB recommendations

Draft amendments propose removing "syrup" from Schedule K exemptions, tightening over-the-counter sales in small villages after Madhya Pradesh cough syrup deaths

Intas has signed an exclusive agreement with SII-backed IntegriMedical to deploy needle-free injection systems across IVF clinics, targeting an all-India rollout by Q1FY26.

Industry experts agree that Gurugram's position as the corporate and commercial hub of NCR is a key draw

The health ministry is unlikely to extend the revised Schedule M GMP deadline for MSME drugmakers beyond December 31, 2025, as it consults states ahead of risk-based inspections

Delhi NCR-based Gaurs Group raised Rs 440 crore via NCDs subscribed by three mutual funds to fund land acquisition, project execution and refinancing, with debentures to list on NSE

Indian Immunologicals Limited said the issue flagged by Australian authorities relates to a single counterfeit batch identified earlier and does not warrant a blanket warning against the vaccine

Firms not complying with norms risk shutdowns once inspections begin next year

Housing sales in the top nine cities fell 16% year on year to 98,019 units in Q4 2025, while new launches declined 10%; developers call it a phase of market realignment

Ajanta Pharma has signed an in-licensing pact with Biocon to market semaglutide across 26 countries in Africa, the Middle East and Central Asia, subject to approvals

The Union Education Ministry is considering extending the One Nation One Subscription scheme to private higher education institutions, following representations from the private education sector

Bharat Biotech has signed a technology transfer agreement with Spain's Biofabri to enable end-to-end manufacturing of MTBVAC, with a Phase 3 study in India expected to start recruitment in Q1 2026

Analysts say the US move to link drug prices to the lowest global benchmarks targets patented medicines, limiting near-term risks for India's largely generic-focused exporters

Healthcare chain to invest Rs 840 crore to expand the facility's capacity to 300 beds, eyes over 1500 beds in the city by 2028

This comes even as affordable homes have been seeing a drop in demand as well as supply in Tier-I markets such as Delhi NCR and Mumbai

Medical visas, supply of drugs and CT scan machines figure in discussions between both countries